Zacks: Brokerages Expect Editas Medicine, Inc. (NASDAQ:EDIT) to Announce -$0.84 Earnings Per Share

Wall Street analysts predict that Editas Medicine, Inc. (NASDAQ:EDITGet Rating) will post earnings of ($0.84) per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Editas Medicine’s earnings. The lowest EPS estimate is ($0.93) and the highest is ($0.72). Editas Medicine posted earnings of ($0.81) per share during the same quarter last year, which suggests a negative year over year growth rate of 3.7%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Editas Medicine will report full year earnings of ($3.41) per share for the current financial year, with EPS estimates ranging from ($3.83) to ($2.85). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.38) per share, with EPS estimates ranging from ($3.85) to ($2.90). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Editas Medicine.

Editas Medicine (NASDAQ:EDITGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.07. Editas Medicine had a negative return on equity of 32.88% and a negative net margin of 721.60%. The company had revenue of $6.80 million for the quarter, compared to analysts’ expectations of $3.85 million. During the same period last year, the firm earned ($0.86) EPS. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis.

Several brokerages have recently issued reports on EDIT. Zacks Investment Research upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Thursday, February 3rd. Robert W. Baird reduced their price objective on Editas Medicine from $44.00 to $33.00 in a research note on Monday, April 18th. Morgan Stanley raised their price objective on Editas Medicine from $16.00 to $17.00 and gave the stock an “underweight” rating in a research note on Tuesday, April 12th. Barclays reduced their price objective on Editas Medicine from $39.00 to $18.00 in a research note on Friday, February 25th. Finally, Chardan Capital reduced their price objective on Editas Medicine from $75.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, February 25th. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $34.40.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Editas Medicine by 3.0% in the first quarter. Vanguard Group Inc. now owns 6,876,539 shares of the company’s stock worth $130,792,000 after buying an additional 202,642 shares during the period. BlackRock Inc. boosted its position in Editas Medicine by 15.5% during the first quarter. BlackRock Inc. now owns 6,275,270 shares of the company’s stock valued at $119,355,000 after purchasing an additional 841,894 shares during the last quarter. State Street Corp boosted its position in Editas Medicine by 51.7% during the fourth quarter. State Street Corp now owns 3,274,607 shares of the company’s stock valued at $86,941,000 after purchasing an additional 1,116,589 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Editas Medicine by 29.8% during the fourth quarter. JPMorgan Chase & Co. now owns 1,464,063 shares of the company’s stock valued at $38,871,000 after purchasing an additional 336,305 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Editas Medicine by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 1,220,371 shares of the company’s stock valued at $32,400,000 after purchasing an additional 25,283 shares during the last quarter. 75.48% of the stock is owned by institutional investors and hedge funds.

Shares of EDIT stock opened at $11.87 on Monday. Editas Medicine has a 1 year low of $9.71 and a 1 year high of $73.03. The stock has a market cap of $814.77 million, a PE ratio of -4.35 and a beta of 2.06. The business’s fifty day moving average is $16.25 and its 200-day moving average is $22.49.

Editas Medicine Company Profile (Get Rating)

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.

Featured Articles

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.